Spectral AI Awarded $31.7 Million of BARDA Funding to Accelerate Development of the DeepView® System

Rhea-AI Summary

Spectral AI (Nasdaq: MDAI) received $31.7 million from BARDA to accelerate feature development of its DeepView® System, an AI burn wound imaging platform. The company will add $9.7 million toward development; BARDA funding supplements $54.9 million previously committed under a contract valued up to $150.0 million. The award is non-dilutive as Spectral AI awaits a determination on market authorization from the U.S. FDA for DeepView.

Positive

• $31.7M in new non-dilutive BARDA funding
• Existing BARDA commitments total $54.9M under a contract up to $150M
• Company committing $9.7M to advance DeepView development

Negative

• DeepView market authorization is pending a U.S. FDA determination
• Project reliant on continued BARDA contracting and future regulatory approval

News Market Reaction – MDAIW

+12.34%

+12.34% Session close to close

In the Mar 19 session, MDAIW gained 12.34%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +12.3% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +12.3% in the session following this news. A strong positive reaction aligns with the clearly supportive nature of BARDA’s new $31.7 million non-dilutive award and the contract’s value of up to $150.0 million. Historically, AI-tagged headlines around DeepView and growth capital have produced an average move of about 5.22%. Investors may weigh this funding alongside prior raises and the pending FDA market authorization decision when assessing how durable any outsized move could be.

Key Figures

New BARDA funding: $31.7 million Company co-funding: $9.7 million BARDA funding to date: $54.9 million +1 more

4 metrics

New BARDA funding $31.7 million Immediate, non-dilutive funding to support DeepView System feature development

Company co-funding $9.7 million Spectral AI’s committed contribution to overall development costs

BARDA funding to date $54.9 million Total funding already committed under current BARDA contract

BARDA contract value $150.0 million Maximum potential value of the existing BARDA contract

Previous AI Reports

5 past events · Latest: Feb 10 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Feb 10	Leadership change	Positive	+2.2%	Appointment of Vincent S. Capone as CEO to drive commercialization.
Feb 02	Awareness initiative	Neutral	-7.3%	Participation in National Burn Awareness Week with education and outreach.
Oct 23	Capital raise	Neutral	+25.7%	$7.6M offering to fund DeepView expansion and commercial readiness.
Sep 19	Industry recognition	Positive	+8.0%	Inclusion in TIME’s World’s Top HealthTech Companies 2025 list.
May 29	Annual meeting	Neutral	-2.5%	Routine approval of directors and auditor at 2025 annual meeting.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

AI-tagged headlines have produced a mix of modest gains and pullbacks, with an average move of about 5.22%, generally aligned with the underlying news tone.

Recent Company History

Over the past year, Spectral AI’s AI-tagged news has centered on advancing its DeepView® burn assessment platform and corporate positioning. Events include a CEO change on Feb 10, 2026 supporting commercialization, awareness initiatives tied to National Burn Awareness Week on Feb 2, 2026, a $7.6 million capital raise on Oct 23, 2025, recognition by TIME’s Top HealthTech list on Sep 19, 2025, and routine 2025 annual meeting voting results on May 29, 2025. The new BARDA funding fits this pattern of building commercial and clinical readiness for DeepView.

Key Terms

Biomedical Advanced Research and Development Authority, BARDA, non-dilutive funding, U.S. Food and Drug Administration, +2 more

6 terms

Biomedical Advanced Research and Development Authority regulatory

"it has received $31.7 million in funding from the Biomedical Advanced Research and Development Authority"

A biomedical advanced research and development authority is a government agency that funds and guides the late-stage development and manufacturing of drugs, vaccines, diagnostics and other health technologies, especially those needed for public health emergencies. For investors it matters because its contracts, grants or technical support act like a bridge and safety net—reducing development risk, accelerating timelines and creating a more reliable path to revenue for companies working on critical medical products.

BARDA regulatory

"funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate"

The Biomedical Advanced Research and Development Authority (BARDA) is a U.S. government agency that funds and helps develop vaccines, drugs, diagnostics and other medical tools needed for large-scale public-health emergencies. It matters to investors because BARDA grants or contracts lower the financial and technical risk of bringing a product to market and can act like a reliable early customer or partner, improving a company’s credibility, funding runway and valuation.

non-dilutive funding financial

"This immediate, non-dilutive funding is being advanced in addition to the $54.9 million"

Non-dilutive funding is money a company raises that does not require issuing new shares or reducing existing owners’ percentage ownership, such as grants, certain loans, contract revenue, or licensing deals. It matters to investors because it lets a company finance growth or research without shrinking shareholder stakes or changing control, much like topping up a car’s gas tank instead of selling part of the car to pay for the trip.

U.S. Food and Drug Administration regulatory

"awaits a determination on market authorization from the U.S. Food and Drug Administration (FDA)"

The U.S. Food and Drug Administration is the federal agency that evaluates and enforces safety, effectiveness and labeling standards for medicines, medical devices, vaccines, food and related products before they reach consumers. For investors it matters because FDA approvals, warnings or recalls determine whether a product can be sold, how quickly it reaches the market and how costly compliance will be—changes that directly affect a company’s revenue, costs and stock value.

FDA regulatory

"awaits a determination on market authorization from the U.S. Food and Drug Administration (FDA)"

The FDA is the U.S. federal agency that evaluates and approves medical drugs, devices, biological therapies and certain foods; think of it as the gatekeeper that decides whether a medical product is safe and effective for patients. For investors, FDA decisions determine whether a company can sell a product, affect expected revenue and introduce regulatory risk, so approvals, rejections or safety warnings can quickly move a company's valuation and stock price.

mass casualty burn incidents medical

"This unmet clinical need is dramatically magnified in the event of mass casualty burn incidents, or BMCIs"

Large-scale events that produce many people with serious burns at once, such as fires, explosions, or chemical exposures, that can overwhelm local medical resources and emergency responders. Investors should care because these incidents can sharply increase demand for burn care products, hospital capacity, rehabilitation services and insurance payouts, and can create regulatory scrutiny or supply-chain pressures—like a sudden traffic jam that strains the whole healthcare system.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DALLAS, March 18, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it has received $31.7 million in funding from the Biomedical Advanced Research and Development Authority (“BARDA”) to accelerate and support additional feature aspects for the Company’s DeepView^® System, its AI-driven burn wound imaging technology. As part of the ongoing partnership, Spectral AI has committed to provide an additional $9.7 million to the total overall development costs associated with these feature advancements.

This immediate, non-dilutive funding is being advanced in addition to the $54.9 million of funding committed to date as part of the Company’s current contract with BARDA (the “BARDA Contract”) valued up to $150.0 million, as the Company awaits a determination on market authorization from the U.S. Food and Drug Administration (FDA) for the DeepView System.

“We are pleased to continue our long-standing partnership with BARDA and are grateful for its ongoing support of the DeepView System, a diagnostic tool that empowers physicians to make quick, data-driven decisions that can improve patient outcomes,” said Vincent Capone, Chief Executive Officer of the Company. “Burn wound assessment is crucial in determining next-step treatment for patients, which currently largely relies on the clinical judgement of physicians. This unmet clinical need is dramatically magnified in the event of mass casualty burn incidents, or BMCIs, where the ability to triage burn patients rapidly and properly would be crucial in allocating valuable resources and managing the surgical burden. The DeepView System technology represents a new paradigm in the assessment of burn wounds and can provide meaningful clinical guidance to physicians in their diagnosis and treatment recommendations."

About the DeepView System

The DeepView System is being developed for use in emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in BMCI. BARDA is part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. This modification to the BARDA Contract supports the continued development and FDA clearance of the DeepView System for commercial marketing and distribution purposes, a major milestone that enables the technology to assist the U.S. government’s BMCI preparedness efforts, and accelerates a number of other development initiatives in Phase II of the existing contract including further development of total body surface area mapping and analysis.

About BARDA and its Support of the DeepView System
This work supports BARDA’s mission to identify medical countermeasures which help counter the effects of a BMCI and address the current limitations within the United States’ burn care infrastructure. According to the American Burn Association, 1.1 million Americans suffer from burn injuries each year, with 500,000 presenting to emergency departments, and 40,000 requiring hospitalization. In contrast to this demand, only two percent of U.S. hospitals have burn centers, and there are only about 250 burn surgeons in the United States.

This project is being supported in whole or in part with federal funds from the Department of Health and Human Services (DHHS); Administration for Strategic Preparedness and Response; and BARDA, under contract number 75A50123C00049. The findings and conclusions have not been formally disseminated by the DHHS and should not be construed to represent any agency determination or policy.

About Spectral AI

Spectral AI, Inc. is a Dallas-based predictive AI company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, with initial applications involving patients with burns. The Company is working to revolutionize the management of wound care by “Seeing the Unknown^®” with its DeepView System. The DeepView System is being developed as a predictive diagnostic device to offer clinicians an objective and immediate assessment of a burn wound’s healing potential prior to treatment or other medical intervention. With algorithm-driven results and a goal of exceeding the current standard of care in the future, the DeepView System is expected to provide fast and accurate treatment insight towards value care by improving patient outcomes and reducing healthcare costs. Spectral AI has been named to TIME’s list of World’s Top HealthTech companies 2025. For more information about the DeepView System, visit www.spectral-ai.com.

Forward-Looking Statements

Certain statements made in this release are “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995, including statements regarding the Company’s strategy, plans, objectives, initiatives and financial outlook. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Company’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. As such, readers are cautioned not to place undue reliance on any forward-looking statements. 

Investors should carefully consider the foregoing factors, and the other risks and uncertainties described in the “Risk Factors” sections of the Company’s filings with the US Securities and Exchange Commission, including the Company’s Registration Statement and the other documents filed by the Company. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. 

Investors:
The Equity Group
Devin Sullivan	Conor Rodriguez
Managing Director	Associate
dsullivan@theequitygroup.com	crodriguez@theequitygroup.com

FAQ

How much BARDA funding did Spectral AI (MDAI) receive on March 18, 2026?

Spectral AI received $31.7 million in BARDA funding on March 18, 2026. According to the company, this award advances feature development of the DeepView System and is provided in addition to previously committed BARDA funds under the contract.

What total BARDA funding has Spectral AI (MDAI) had committed under its contract so far?

BARDA commitments total $54.9 million to date under the contract. According to the company, the new $31.7 million is being advanced in addition to that $54.9 million toward DeepView development.

How much is Spectral AI (MDAI) contributing to DeepView development alongside BARDA?

Spectral AI has committed to contribute $9.7 million to the development costs. According to the company, that contribution supplements BARDA funding to support additional DeepView feature advancements.

Does the BARDA award dilute Spectral AI (MDAI) shareholders?

The BARDA funding is described as non-dilutive, so it does not issue equity to BARDA. According to the company, the award provides cash support without diluting existing shareholders while development continues.

What regulatory step is pending for Spectral AI's (MDAI) DeepView System after the BARDA award?

Spectral AI is awaiting a U.S. FDA determination on market authorization for DeepView. According to the company, BARDA funding supports development as the company awaits that regulatory decision, which will affect commercialization timing.